Cell lines

3201 (feline lymphoid) cells, 81C (sarcoma-positive, leukemia-negative feline lung fibroblast) cells, and primary feline bone marrow cells

Reaction Conditions

0 ~ 384 μM zalcitabine

Applications

Zalcitabine (5 ~ 10 μM) inhibited feline leukemia virus (FeLV) infection of feline lymphoid cells by greater than 80%, while 6.07 ~ 12.13 μM zalcitabine was required to similarly inhibit infection of feline fibroblasts. However, 43 ~ 384 μM zalcitabine was needed to inhibit FeLV infection of primary bone marrow cells by greater than 80%.

Animal models

Cats challenged intravenously with FeLV 1 ~ 3 days after drug treatment began

Dosage form

22, 15, 10, and 5 mg/kg per h

Administered by continuous intravenous infusion for 28 days

Applications

Doses of 22 and 15 mg/kg per h were extremely toxic, causing death in 8 of 10 cats. The 10 mg/kg per h dose was slightly toxic, causing chronic progressive thrombocytopenia over the 28-day treatment period. Of 10 cats given 10 or 5 mg of zalcitabine per kg per h, only one was completely protected from FeLV antigenemia. However, conversion to positive FeLV antigenemia status was delayed by 2 ~ 7 weeks in seven of nine remaining animals.

Note

The technical data provided above is for reference only.

References:

1. Polas PJ, Swenson CL, Sams R, et al. In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrobial Agents and Chemotherapy, 1990, 34(7): 1414-1421.